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a  b  s  t  r  a  c  t
Neurotrophic  factors  regulate  the  survival  and  growth  of  neurons,  and  inﬂuence  synaptic  efﬁciency  and
plasticity.  Several  studies  suggest  the  existence  of  a relationship  between  changes  in neurotrophic  levels
and  bipolar  disorder  (BD).  The  glial  cell-line  derived  neurotrophic  factor  (GDNF)  inﬂuences  monoaminer-
gic  neurons  and glial  cells,  but its  role  in BD  patients  is  controversial.  In order  to  elucidate  it  we  evaluated
plasma  levels  of  GDNF  in  a sample  of  70 BD  patients  (35  in  mania  and  35  in  euthymia)  and  compared
with  50  healthy  controls  matched  for  age, gender  and  educational  levels.  GDNF  plasma  levels  were  mea-
sured  by  enzyme-linked  immunosorbent  assay  (ELISA).  Patients  were  assessed  by  a  Mini-Internationallial  derived neurotrophic factor
DNF
ood biomarker
Neuropsychiatric  Interview  (MINI-plus),  Young  Mania  and  Hamilton  Depression  Rating  Scales.  Plasma
GDNF  levels  were  signiﬁcantly  increased  in BD  patients  in  euthymia  compared  with  BD  patients  in  mania
and  healthy  controls  (p < 0.05).  GDNF  plasma  levels  were  correlated  with  age  ( = 0.30,  p  < 0.05)  and  neg-
atively  correlated  with  manic  symptoms  in  BD  patients  (  =  −0.54, p <  0.05).  Our  results  provide  evidence
that  peripheral  levels  of  GDNF  are  related  with  different  mood  states  in  BD,  reinforcing  the  involvement
 its pof  neurotrophic  factors  in
ipolar disorder (BD) is a chronic, recurrent and one of the most
evere psychiatric illnesses. The cardinal feature that distinguishes
D from recurrent major depressive disorder is the presence of at
east one episode of mania or hypomania during lifetime. BD type I
resents at least one mania episode and affects approximately one
ercent of the population worldwide [7].
Growing evidence shows that BD is associated with abnormal-
ties in neural circuits and synapses, as well in plastic processes
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nternational Neuropsychiatric Interview; YMRS, Young Mania Rating Scale.
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[23]. Post-mortem study of the brain of BD patients demonstrates
abnormalities in prefrontal and cingulate grey matter areas mostly
characterized by reduced number, density and size of glial pop-
ulation [20]. Dysregulation of neurotrophins imbalance has been
suggested as one of the mediators and markers of neuroanatomical
brain changes in BD [14].
Neurotrophins  play an important role in synaptic plasticity
and have shown to be altered in patients with BD. Brain-derived
neurotrophic factor (BDNF) is the most studied neurotrophin
in BD. In a recent meta-analysis, Lin [15] showed that levels
of BDNF are reduced during mania and depression when com-
pared to healthy controls, but not in euthymic patients. A related
neurotrophin that has also been associated with synaptic plas-
ticity is the glial cell-line derived neurotrophic factor (GDNF)
[2,9]. Until now only a few studies have evaluated GDNF lev-
els in BD patients [19,21,26,31] and it is still unclear whether
GDNF levels are associated with BD and/or with different mood
states.
Open access under the Elsevier OA license.In order to clarify the role of GDNF in BD, the aims of this study
were to evaluate plasma levels of GDNF in a sample of BD patients
and to investigate whether mood state (i.e. mania) inﬂuences GDNF
circulating levels in BD.
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Table 1
Clinical and demographic features of controls and bipolar disorders (BD) subjects.
Healthy controls (N = 50) BD patients (N = 70) p-Values
Mania (N = 35) Euthymia (N = 35)
Female gender (frequency, %) 70.00 62.86 77.14 >0.05a
Age in years (mean ± SD) 47.48 ± 7.64 52.54 ± 12.41 47.29 ± 9.07 >0.05c
Education level in years (mean ± SD) 9.76 ± 3.31 10.49 ± 2.91 9.63 ± 4.02 >0.05c
YMRS (mean ± SD) – 25.80 ± 7.05 0.83 ± 1.67 <0.0001b
HDRS (mean ± SD) – 3.26 ± 3.72 2.43 ± 2.81 >0.05b
Age of ﬁrst mood episode (mean ± SD) – 28.58 ± 10.36 24.66 ± 9.60 >0.05b
Age of ﬁrst depressive episode (mean ± SD) – 29.06 ± 10.95 25.37 ± 9.46 >0.05b
Age of ﬁrst manic episode (mean ± SD) – 27.31 ± 10.43 32.06 ± 12.60 >0.05b
Duration of illness (mean ± SD) – 26.69 ± 15.17 22.51 ± 11.15 >0.05b
Number of hospitalizations (mean ± SD) – 10.70 ± 13.47 6.37 ± 5.01 >0.05b
Suicide attempt (frequency, %) – 20.00 40.00 >0.05a
Medication in use (frequency, %)
Lithium – 70.00 48.28 >0.05a
Anticonvulsants – 66.67 56.62 >0.05a
Antipsychotics – 50.00 41.40 >0.05a
N: number; YMRS: Young Mania Rating Scale; HDRS: Hamilton Depression Rating Scale; BD: bipolar disorder.
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wChi-square test.
b Mann–Whitney test.
c Kruskal–Wallis test.
Seventy BD type I patients (35 in mania and 35 in euthymia) and
fty healthy controls matched for gender, age and years of study
ere recruited for this study in a public hospital as in-patient or
ut-patient admission. The control group was recruited from the
ocal population and they did not have any personal or family his-
ory of psychiatric disorders, suicide behavior, cognitive deﬁcit or
linical diseases.
All procedures described in this study received approval from
he local clinical research ethics committee and are in accordance
ith the Helsinki Declaration of 1975. Written informed consent
as obtained from all patients and healthy subjects prior to con-
ucting any study procedures.
All participants were over the legal age of 18 years old. Subjects
ith dementia and previous diagnosis of any neurodegenerative
isorders, infectious or autoimmune diseases, or who had used cor-
icosteroids, non-steroidal anti-inﬂammatory drugs or antibiotics 4
eeks before the entry into the study were excluded. As GDNF lev-
ls could be inﬂuenced by chronic renal failure [18], no subjects
ith this condition was included in the study. Psychiatric diag-
oses were based on DSM-IV-TR criteria [1] and were performed
ollowing a structured clinical interview (Mini-International Neu-
opsychiatric Interview, MINI-plus) [3,25].  Healthy controls were
ssessed by MINI-plus to exclude any psychiatric condition. The
everity of manic and depressive symptoms was assessed by
he Young Mania Rating Scale (YMRS) [28] and the Hamilton
epression Rating Scale, 17-item version (HDRS) [10], respectively.
uthymia was deﬁned by YMRS score and HDRS score lower than
 points for at least four weeks.
All blood samples were drawn at the moment of the clinical
ssessment. Five milliliters of blood was drawn from each sub-
ect by venipuncture into a vacuum tube containing heparin, and
as immediately centrifuged twice at 3000 × g for 10 min, and
lasma was kept frozen at −70 ◦C until assayed. Plasma concentra-
ion of GDNF was measured according to the procedure provided
y the manufacturer using sandwich ELISA kits for GDNF (DuoSet,
&D Systems, Minneapolis, MN,  USA). All samples were assayed
n duplicate. The detection limits for these assays were 10 pg/mL.
oncentration is expressed as pg/mL.
Statistical analyses were performed using SPSS software ver-
ion 17.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were
sed to report socio-demographic and clinical characteristics of the
ample. Association between dichotomous variables was  assessed
ith chi-square test or Fisher’s exact test when appropriate. Allvariables were tested for normality of distribution by means of
the Kolmogorov–Smirnov test and all data were non-normally dis-
tributed. Two groups (patients vs. controls) were compared by
Mann–Whitney test. Differences between three groups (patients
in mania vs. patients in euthymia vs. controls) were compared
with Kruskal–Wallis test. Multiple comparisons among levels were
checked with Dunn’s post hoc test. Spearman’s correlation analy-
sis was performed to examine the relationship of GDNF levels with
age, length of illness, education. All statistical tests were two-tailed
and were performed using a signiﬁcance level of alpha = 0.05.
The demographic and clinical features of all groups are shown
in Table 1. There were no statistical signiﬁcant differences between
BD patients groups and the healthy control group regarding gender,
age and years of study. Among BD patients, there were no marked
variations among the age of ﬁrst mood episode, length of disease,
number of hospitalizations or medications in use. All patients were
medicated.
There was  no signiﬁcant differences in GDNF plasma levels
between BD patients and healthy controls (mean ± SD,  pg/ml;
55.78 ± 78.42, 39.78 ± 57.89, respectively, p > 0.05) (Fig. 1A). When
comparing BD sub-groups (categorized according to mood state)
with healthy controls, GDNF plasma levels were higher in euthymic
BD patients in comparison with manic and healthy controls
(mean ± SD, pg/ml; euthymia: 76.74 ± 95.26; mania: 34.09 ± 48.80;
controls: 40.52 ± 58.99; p < 0.05), post hoc analysis (euthymia vs.
mania, p < 0.05; euthymia vs. healthy control, p < 0.05; mania vs.
healthy control, p > 0.05) (Fig. 1B). There was no signiﬁcant differ-
ence between BD patients in mania and controls, but there was a
tendency of reduced levels in patients. There was a predominance
of female subjects in all groups, but there was no difference in GDNF
plasma levels when comparing gender.
GDNF plasma levels were positively correlated with age in
BD patients ( = 0.30, p < 0.05); BD patients in euthymia ( = 0.39,
p < 0.05); and BD patients in mania ( = 0.47, p < 0.05). GDNF
plasma levels were negatively correlated with YMRS in BD patients
( = −0.54, p < 0.05); BD patients in euthymia ( = −0.47, p < 0.05);
and BD patients in mania ( = −0.33, p > 0.05). There was  no asso-
ciation between GDNF levels and severity of depressive symptoms
or duration of illness. Correlation between age and plasma levels of
GDNF was not observed in healthy controls.
GDNF levels did not differ in BD categorized according to the
presence of clinical comorbities (blood arterial hypertension, dia-
betes mellitus, dislipidemia, and thyroid diseases), psychiatric
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tig. 1. (A) Plasma GDNF levels in controls and bipolar disorder (BD) patients. (B)
lasma GDNF levels in controls, euthymia and mania.
omorbities (i.e. generalized anxiety disorder, panic disorder, pre-
iously or actual episode of psychosis), dependence of substances
including alcohol and tobacco), previous attempt of suicide and
revious depressive episode. Plasma GDNF levels did not differ in
D patients according to the medication in use, such as lithium,
nti-convulsants or anti-psychotics (data not show).
In the present study, plasma levels of GDNF were signiﬁcantly
ncreased in euthymic BD patients in comparison with healthy con-
rols and BD patients in mania. In BD patients, plasma levels of
DNF were negatively correlated with the severity of mania and
ositively correlated with age. Our results are in line with the
ypothesis that altered levels of neurotrophic factors are related
ith mood changes in BD patients [5,6,14,15,27].  However it seems
hat GDNF may  present a different balance in comparison with
DNF levels in BD [15].
This is the ﬁrst study to show higher plasma levels of GDNF in
uthymic BD patients in comparison with healthy controls. Otsuki
t al. [19] did not ﬁnd any difference in RNA levels of GDNF when the
uthors compared BD patients in depression or after their remis-
ion and controls. Rosa et al. [21] reported increased serum levels
f GDNF in BD patients in depression and mania compared with
ealthy controls, without difference between euthymic patients
nd healthy controls. Two studies showed decreased levels of GDNF
n BD patients in euthymia [26] and mania or depression [31]. Inter-
stingly, Zhang et al. [31] showed that BD patients evolved with
ncreased serum levels of GDNF after remission of a depression or
ania episode.
In the past, the role of GDNF in the development and
aintenance of the nigrostriatal system and its relation with
opaminergic system was only implicated in Parkinson’s disease
hysiopathology. Otherwise recent evidence has suggested that
he up-regulation of GDNF by astrocytes and microglia may  be a
rotective mechanism to restrain neuronal loss observed in dif-
erent types of brain diseases [17,22]. Repeated mood episodes
nd aging seem to present a cumulative load to BD patients and
ay  be associated with neurotoxicity [13]. Therefore one possible
xplanation to our results is that mood episodes might be toxic
o the brain, reducing GDNF levels. As the person gets older, inetters 502 (2011) 103– 106 105
order to prevent detrimental effects of mood episodes, GDNF levels
would be increased during euthymic states. Reinforcing our results,
two previous studies with major depression patients have shown
decreased levels of GDNF during acutely ill episode and increased
levels of GDNF after mood recovery [29,30].
There are some limitations in our study. First, all patients were
medicated (mood stabilizing agents, antipsychotics and/or antide-
pressants) and it is not possible to exclude the effect of drugs in
circulating levels of GDNF. Zhang et al. [31] did not ﬁnd any effect
of medication in GDNF levels. Conversely, data from in vitro studies
demonstrate increased levels of GDNF in the presence of antide-
pressants and mood stabilizing agents [4,8,11,24].  Due to the high
probability of disease relapse upon drug withdrawal, it is not rec-
ommended or ethically acceptable to interrupt drugs in order to
rule out the impact of psychotropic drugs in BD patients. Second, it
is unknown whether peripheral GDNF levels correlate with GDNF
concentration in the central nervous system [12,16]. The number
of subjects included in the present study and the strict inclusion
criteria must be considered strengths of our work.
In conclusion, our results are in line with previous studies and
suggest the role of neurotrophic factors in BD physiopathology.
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